Pesquisa | BVS Bolivia

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.

Rampotas, Alex; Carter-Brzezinski, Luke; Somervaille, Tim C P; Forryan, James; Panitsas, Fotios; Harrison, Claire; Witherall, Ruth; Innes, Andrew J; Wallis, Louise; Butt, Naumann M; Psaila, Bethan; Mead, Adam J; Carter, Matthew; Godfrey, Anna L; Laing, Heather; Garg, Mamta; Francis, Sebastian; Ewing, Joanne; Teh, Chun Huat; Cowen, Hannah Bibi; Dyer, Peter; McConville, Conall; Wadelin, Frances; Sahra, Ali; McGregor, Andrew; Kulakov, Elizabeth; McLornan, Donal P; Lambert, Jonathan.

Blood ; 143(2): 178-182, 2024 Jan 11.

Artigo em Inglês | MEDLINE | ID: mdl-37963262

RESUMO

ABSTRACT: Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.

Assuntos

Transtornos Mieloproliferativos , Pirazóis , Pirimidinas , Neoplasias Cutâneas , Humanos , Estudos Prospectivos , Transtornos Mieloproliferativos/tratamento farmacológico , Nitrilas , Neoplasias Cutâneas/tratamento farmacológico

Ver mais detalhes

ENVIAR RESULTADO:

Exportar

Imprimir

RSS

XML

RESUMO

Assuntos

ENVIAR RESULTADO:

SELEÇÃO DE REFERÊNCIAS

DETALHE DA PESQUISA